An in-progress, open-label, multi-centre study (SAILOR) evaluating whether a steroid-free immunosuppressive protocol, based on ATG induction and a low tacrolimus dose, reduces the incidence of new onset diabetes after transplantation

Transplantation Research

Volumn 3, Issue 1, 2014, Pages

  Ekberg, Jana ^a   Ekberg, Henrik ^b   Jespersen, Bente ^c   Källen, Ragnar ^b   Skov, Karin ^c   Olausson, Michael ^a   Mjörnstedt, Lars ^a   Lindnér, Per ^a  

^a SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

diabetes; immunosuppression; renal transplantation

Indexed keywords

BASILIXIMAB; INTERLEUKIN 2 RECEPTOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GRAFT SURVIVAL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

EID: 84930188957     PISSN: None     EISSN: 20471440     Source Type: Journal    
DOI: 10.1186/2047-1440-3-12     Document Type: Article

References (29)

1. Vanrenterghem Y, van Hooff JP, Squifflet JP, Salmela K, Rigotti P, Jindal RM, Pascual J, Ekberg H, Sicilia LS, Boletis JN, Grinyo JM, Rodriguez MA, . European Tacrolimus/MMF Renal Transplantation Study Group Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 2005, 5(1):87-95. 10.1111/j.1600-6143.2004.00638.x, 15636615, European Tacrolimus/MMF Renal Transplantation Study Group.
2. Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P, Mariat C, Margreiter R, Capdevilla L, Lang P, Vialtel P, Ortuño-Mirete J, Charpentier B, Legendre C, Sanchez-Plumed J, Oppenheimer F, Kessler M, . CARMEN Study Group Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005, 79(7):807-814. 10.1097/01.TP.0000154915.20524.0A, 15818323, CARMEN Study Group.
3. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF, . ELITE-Symphony Study Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007, 357(25):2562-2575. 10.1056/NEJMoa067411, 18094377, ELITE-Symphony Study.
4. Kasiske B, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003, 3:178-185. 10.1034/j.1600-6143.2003.00010.x, 12603213.
5. Hatamizadeh P, Molnar MZ, Streja E, Lertdumrongluk P, Krishnan M, Kovesdy CP, Kalantar-Zadeh K. Recipient-related predictors of kidney transplantation outcomes in the elderly. Clin Transplant 2013, 27(3):436-443. 10.1111/ctr.12106, 3674215, 23516994.
6. Valderhaug TG, Jenssen T, Hartmann A, Midtvedt K, Holdaas H, Reisaeter AV, Hjelmesaeth J. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 2009, 88:429-434. 10.1097/TP.0b013e3181af1f53, 19667949.
7. First MR, Dhadda S, Croy R, Holman J, Fitzsimmons WE. New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials. Transplantation 2013, 96(1):58-64. 10.1097/TP.0b013e318293fcf8, 23619735.
8. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jensen T, Campistol JM, Uchida K, Peskovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007, 7:1506-1514. 10.1111/j.1600-6143.2007.01749.x, 17359512.
9. Aasebo W, Midtvedt K, Valderhaug TG, Leivestad T, Hartman A, Varberg Riesaeter A, Jensen T, Holdass H. Impaired glucose homeostasis in renal transplant recipients receiving basiliximab. Nephrol Dial Transplant 2010, 25:1289-1293. 10.1093/ndt/gfp617, 19934089.
10. Prasad N, Gurjer D, Bhaduaria D, Gupta A, Srivastava A, Kaul A, Jaiswal A, Yadav B, Yadav S, Sharma R. Is basiliximab induction, a novel risk factor for new onset diabetes mellitus after transplantation for living donor renal allograft recipients?. Nephrology (Carlton) 2014, 19:244-250. 10.1111/nep.12209, 24447227.
11. Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, Tueros L, Hanson L, Rosen A, Ruiz P, Miller J. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one-year follow-up. Transplantation 2008, 86(1):67-74. 10.1097/TP.0b013e3181734b4a, 18622280.
12. Libório AB, Mendoza TR, Esmeraldo RM, Oliveira ML, Paes FJ, Silva Junior GB, Daher EF. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin. Int Immunopharmacol 2011, 11:1832-1836. 10.1016/j.intimp.2011.07.012, 21835269.
13. Alexander JW, Goodman HR, Cardi M, Austin J, Goel S, Safdar S, Huang S, Munda R, Fidler JP, Buell JF, Hanaway M, Susskind B, Roy-Chaudhury P, Trofe J, Alloway R, Woodle ES. Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation. Transpl Int 2006, 19(4):295-302. 10.1111/j.1432-2277.2006.00280.x, 16573545.
14. Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D. New-onset diabetes after renal transplantation: risk assessment and management. Diabetes Care 2012, 35(1):181-188. 10.2337/dc11-1230, 3241330, 22187441.
15. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Baldwin WM, Bracamonte ER, Broecker V, Cosio F, Demetris AJ, Drachenberg C, Einecke G, Gloor J, Glotz D, Kraus E, Legendre C, Liapis H, Mannon RB, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Rodriguez ER, Seron D, Seshan S, Suthanthiran M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010, 10(3):464-471. 10.1111/j.1600-6143.2009.02987.x, 20121738.
16. Van Duijnhoven EM, Boots JM, Christiaans MH, van Hooff JP. Metabolic aspects of tacrolimus in renal transplantation. Consequences for the choice of an immunosuppressive regimen and for the management of post-transplant diabetes mellitus. Minerva Urol Nefrol 2003, 55:1-10.
17. Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomized trial data. BMJ 2005, 331:810-814. 10.1136/bmj.38569.471007.AE, 1246079, 16157605.
18. Van Duijnhoven EM, Christiaans MH, Boots JM, Nieman FH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002, 13:213-220.
19. Claes K, Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol Dial Transplant 2012, 27:850-857. 10.1093/ndt/gfr238, 21617197.
20. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003, 3(3):306-311. 10.1034/j.1600-6143.2003.00005.x, 12614286.
21. Valderhaug TG, Hjelmesaeth J, Hartman A, Röislien J, Bergrem HA, Leivestad T, Line PD, Jensen T. The association of early post-transplant glucose levels with long-term mortality. Diabetologia 2011, 54:1341-1349. 10.1007/s00125-011-2105-9, 3088823, 21409415.
22. Stevens RB, Mercer DF, Grant WJ, Freifeld AG, Lane JT, Groggel GC, Rigley TH, Nielsen KJ, Henning ME, Skorupa JY, Skorupa AJ, Christensen KA, Sandoz JP, Kellogg AM, Langnas AN, Wrenshall LE. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. Transplantation 2008, 85:1391-1399. 10.1097/TP.0b013e3181722fad, 18497677.
23. Mjörnstedt L, Olausson M, Lindholm L, Söderström T, Brynger H. Mechanisms maintaining transplantation tolerance in antithymocyte globulin treated rats. Transplantation 1987, 44(5):669-673. 10.1097/00007890-198711000-00015, 2961112.
24. Preville X, Flacher M, LeMauff B, Beauchard S, Davelu P, Tiollier J, Revillard JP. Mechanisms involved in anti-thymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001, 71:460. 10.1097/00007890-200102150-00021, 11233911.
25. Matas AJ, Kandaswamy R, Gillingham KJ, McHugh L, Ibrahim H, Kasiske B, Humar A. Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant 2005, 5(10):2473-2478. 10.1111/j.1600-6143.2005.01051.x, 16162197.
26. Gourishankar S, Houde I, Keown PA, Landsberg D, Cardella CJ, Barama AA, Dandavino R, Shoker A, Pirc L, Wrobel MM, Kiberd BA. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin J Am Soc Nephrol 2010, 5(7):1282-1289. 10.2215/CJN.09091209, 2893067, 20498245.
27. de Winter BC, Mathôt RA, van Hest RM, van Gelder T. Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?. Expert Opin Drug Metab Toxicol 2007, 3(2):251-261. 10.1517/17425255.3.2.251, 17428154.
28. Sellares J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012, 12(2):388-399. 10.1111/j.1600-6143.2011.03840.x, 22081892.
29. Wiebe C. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012, 12:1157-1167. 10.1111/j.1600-6143.2012.04013.x, 22429309.